Healthlead Public Company Limited

As of June 30, 2026, Healthlead Public Company Limited carries a market capitalization of 1.42B, placing it among publicly traded companies globally. Its enterprise value stands at 1.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Healthlead Public Company Limited has 254.09M shares outstanding.

As of June 30, 2026, Healthlead Public Company Limited trades at a trailing price-to-earnings ratio of 24.65. The price-to-sales ratio is 0.66, and the price-to-book ratio stands at 1.62.

As of June 30, 2026, Healthlead Public Company Limited trades at an EV/EBITDA multiple of 6.96 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.59 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 14.59 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Healthlead Public Company Limited trades at an EV/FCF ratio of 12.07, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.30B versus a market cap of 1.42B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Healthlead Public Company Limited maintains a current ratio of 3.34, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 33.24, indicating elevated leverage, while an interest coverage ratio of 10.73 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Healthlead Public Company Limited posted a return on equity (ROE) of 6.44, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.81 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.12, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.01, useful for judging operating efficiency across full business cycles. Inventory turnover of 5.01 indicates how many times Healthlead Public Company Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Healthlead Public Company Limited recorded 15.02M in income tax expense. That works out to an effective tax rate of 20.17, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 74.47M, leaving 59.45M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Healthlead Public Company Limited's stock has declined approximately 40.27% over the past 52 weeks. The 50-day moving average sits at 4.69, while the 200-day moving average is 5.93.

Over the twelve months ended June 30, 2026, Healthlead Public Company Limited generated 2.22B in revenue and converted that into 59.45M in net income, yielding earnings per share of 0.23. EBITDA reached 187.19M, while operating income came in at 89.34M.

As of June 30, 2026, Healthlead Public Company Limited holds 411.11M in cash and equivalents against 291.89M in total debt, resulting in a net debt position of -38.86M. Total book value stands at 878.17M, with working capital of 570.78M providing operational flexibility.

Healthlead Public Company Limited produced 119.72M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -25.64M in capital expenditures, free cash flow totaled 94.08M - equivalent to 0.36 per share.

Over the twelve months ended June 30, 2026, Healthlead Public Company Limited posted a gross margin of 24.41, reflecting its pricing power and cost economics. The operating margin of 4.02 and net profit margin of 2.67 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Healthlead Public Company Limited paid dividends of 0.22 per share. The dividend payout ratio of 95.29 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 6.42, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 14.67, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Healthlead Public Company Limited shareholders.

As of June 30, 2026, Healthlead Public Company Limited has an Altman Z-Score of 4.05, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.